Skip to main content
. 2021 Mar 30;23(6):412. doi: 10.3892/mmr.2021.12051

Figure 5.

Figure 5.

RIP3 serves a major role in the cell necrosis induced by ABT-737 treatment. (A) Expression levels of RIP3 in UMUC3 and 5637 cells after treatment with RIP3 siRNA for 12 h were analyzed via western blotting, and the results were (B) semi-quantified. (C) Protein expression levels of HMGB1, ZBP1 and MLKL were analyzed in RIP3-KD UMUC3 and RIP3-KD 5637 cells treated with Z-VAD-FMK combined with ABT-737 for 12 h. The results were semi-quantified in (D) UMUC3 and (E) 5637 cells. (F) Transwell invasion assays were performed with RIP3-KD UMUC3 cells. (G) Quantification of Transwell assay results. (H) MTT assays were performed to examine the viability of RIP3-KD UMUC3 cells treated with Z-VAD-FMK combined with ABT-737 for 12 h. (I) Transwell invasion assays of RIP3-KD 5637 cells. (J) Quantification of Transwell assay results. (K) MTT assays were performed to examine the viability of RIP3-KD 5637 cells treated with Z-VAD-FMK combined with ABT-737 for 12 h. (scale bar=50 µm) *P<0.05 vs. siRNA NC or control. OD, optical density; ZBP1, Z-DNA binding protein 1; RIP, receptor-interacting protein; HMGB1, high mobility group box 1; MLKL, mixed-lineage kinase domain-like protein; siRNA, small interfering RNA; NC, negative control; KD, knockdown.